Program Guidelines - Partner

Program Operations Guidelines for STD Prevention
Partner Services

Appendix PS-A

INTERVIEW PERIODS BY DISEASE

Disease Code	Disease Type	Interview Period
200/300	Chlamydia/Gonorrhea	Symptomatic—60 days prior to onset of symptoms through the date of treatment Asymptomatic cases—60 days prior to treatment
490	Pelvic Inflammatory Disease	60 days prior to onset of symptoms through the date of treatment
710	Primary Syphilis	90 days prior to date of onset of primary lesion through the date of treatment
720	Secondary Syphilis	6.5 months prior to date of onset of secondary symptoms through the date of treatment
730	Early Latent Syphilis*	1 year prior to start of treatment
900/950	HIV/AIDS	1 year prior to the date of positive test through the date of posttest counseling (extended interview period may be warranted by individual circumstances) 10-year interview period for current or any previous spouses
Note: Interview periods may be modified if a history of symptoms, a negative test result, or incidental treatment are documented. If symptom history is questionable, a maximum interview period should be used. If the patient claims no partners during the interview period, then the most recent partner before the interview period should be elicited and notified. * Many syphilis cases cannot be staged until after the case is closed. When the stage of syphilis is undetermined at the time of interview, a one-year interview period should be used. That is, STD prevention programs should initially interview a patient as early latent syphilis (730) and then, if appropriate, reclassify at case closure as late latent syphilis (745), latent syphilis of unknown duration (740), or not syphilis (serofast). To reclassify an early latent case as late latent or unknown duration, the following criteria must be met: no history of exposure to a known case of syphilis (as determined by interviewing the case and following up on sex partners), no history of symptoms in the last year, no history of a negative blood test in the last year, and no rise in titer of two dilutions or more. A case should be reported even if treatment is not verified.

Table of Contents

Page last modified: August 16, 2007
Page last reviewed: August 16, 2007 Historical Document
Content Source: Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention